NCT07462377
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 6 → 12 locations
- Notable Eligibility criteria expanded, about 8 words
- Study sites: 6 to 8
- Secondary endpoints: details revised at 4 of 6 entries
- Study description revised
- Minor Study sites revised (6)v6
- Minor Site details revised at 1 of 6 sitesv5
- Minor Start date changed from estimate of Apr 2026 to Mar 31, 2026
- Site details revised at 1 of 6 sites
Show 2 earlier versionsHide 2 earlier versions
- Minor Study sites: 5 to 6v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised at 5 of 5 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Evaluation of the safety and tolerability of EPI-326
Timeframe: Up to 3 years.
Determination of the recommended dose and schedule for EPI-326 administration
Timeframe: Up to 3 years.
Secondary (6)
Determination of maximum (Cmax) and minimum (Cmin) plasma concentration
Determination of area under the concentration-time curve (AUC)
Determination of clearance (CL) from the blood
Determination of volume of distribution (Vd)
Objective response rate (ORR)
Show 1 moreShow less
Duration of response (DOR)
Arms and interventions
EPI-326Experimental
Experimental: Dose Escalation
Drugs: EPI-326
Sites
12 sites in 3 countries
United States 6, South Korea 4, Taiwan 2